Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration

Vaccine

Volumn 30, Issue 32, 2012, Pages 4884-4891

  de Haan, Aalzen ^a   Haijema, Bert Jan ^b   Voorn, Petra ^b   Meijerhof, Tjarko ^a   van Roosmalen, Maarten L ^b   Leenhouts, Kees ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Mucosis BV   (Netherlands)

Author keywords

Adjuvant; Bacterium like particles; IgA; Influenza; Intranasal; Vaccine

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BACTERIAL LIKE PARTICLE; BACTERIAL PHENOMENA AND FUNCTIONS; CONTROLLED STUDY; CROSS PROTECTION; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA A (H1N1); MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; VIRUS TITRATION; WEIGHT REDUCTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; ANTIGENS, VIRAL; CROSS PROTECTION; HEMAGGLUTINATION INHIBITION TESTS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; LACTOCOCCUS LACTIS; LUNG; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VACCINES, INACTIVATED;

EID: 84862587725     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.032     Document Type: Article

References (24)

1. Liew F.Y., Russell S.M., Appleyard G., Brand C.M., Beale J. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity. European Journal of Immunology 1984, 14(4):350-356.
2. Belyakov I.M., Ahlers J.D. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?. Journal of Immunology 2009, 183(11):6883-6892.
3. Slutter B., Hagenaars N., Jiskoot W. Rational design of nasal vaccines. Journal of Drug Targeting 2008, 16(1):1-17.
4. Mestecky J., Moldoveanu Z., Elson C.O. Immune response versus mucosal tolerance to mucosally administered antigens. Vaccine 2005, 23(15):1800-1803.
5. Sun J.B., Czerkinsky C., Holmgren J. Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit. Scandinavian Journal of Immunology 2010, 71(1):1-11.
6. Fujihashi K., Koga T., van Ginkel F.W., Hagiwara Y., McGhee J.R. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine 2002, 20(19-20):2431-2438.
7. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. New England Journal of Medicine 2004, 350(9):896-903.
8. van Roosmalen M.L., Kanninga R., El Khattabi M., Neef J., Audouy S., Bosma T., et al. Mucosal vaccine delivery of antigens tightly bound to an adjuvant particle made from food-grade bacteria. Methods 2006, 38(2):144-149.
9. Audouy S.A., van Roosmalen M.L., Neef J., Kanninga R., Post E., van Deemter M., et al. Lactococcus lactis GEM particles displaying pneumococcal antigens induce local and systemic immune responses following intranasal immunization. Vaccine 2006, 24(26):5434-5441.
10. Audouy S.A., van Selm S., van Roosmalen M.L., Post E., Kanninga R., Neef J., et al. Development of lactococcal GEM-based pneumococcal vaccines. Vaccine 2007, 25(13):2497-2506.
11. Ramasamy R., Yasawardena S., Zomer A., Venema G., Kok J., Leenhouts K. Immunogenicity of a malaria parasite antigen displayed by Lactococcus lactis in oral immunisations. Vaccine 2006, 24(18):3900-3908.
12. Ramirez K., Ditamo Y., Rodriguez L., Picking W.L., van Roosmalen M.L., Leenhouts K., et al. Neonatal mucosal immunization with a non-living, non-genetically modified Lactococcus lactis vaccine carrier induces systemic and local Th1-type immunity and protects against lethal bacterial infection. Mucosal Immunology 2010, 3(2):159-171.
13. Saluja V., Amorij J.P., van Roosmalen M.L., Leenhouts K., Huckriede A., Hinrichs W.L., et al. Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant. AAPS Journal 2010, 12(2):109-116.
14. Wood J.M., Schild G.C., Newman R.W., Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. Journal of Biological Standardization 1977, 5(3):237-247.
15. Haan L., Verweij W.R., Holtrop M., Brands R., van Scharrenburg G.J., Palache A.M., et al. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity. Vaccine 2001, 19(20-22):2898-2907.
16. Renegar K.B., Small P.A. Passive transfer of local immunity to influenza virus infection by IgA antibody. Journal of Immunology 1991, 146(6):1972-1978.
17. Renegar K.B., Small P.A. Immunoglobulin A mediation of murine nasal anti-influenza virus immunity. Journal of Virology 1991, 65(4):2146-2148.
18. Saluja V., Visser M.R., Ter Veer W., van Roosmalen M.L., Leenhouts K., Hinrichs W.L., et al. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles. Vaccine 2010, 28(50):7963-7969.
19. Huber V.C., McKeon R.M., Brackin M.N., Miller L.A., Keating R., Brown S.A., et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clinical and Vaccine Immunology 2006, 13(9):981-990.
20. Saluja V., Visser M.R., van Roosmalen M.L., Leenhouts K., Huckriede A., Hinrichs W.L., et al. Gastro-intestinal delivery of influenza subunit vaccine formulation adjuvanted with Gram-positive enhancer matrix (GEM) particles. European Journal of Pharmaceutics and Biopharmaceutics 2010, 76(3):470-474.
21. Borsutzky S., Kretschmer K., Becker P.D., Muhlradt P.F., Kirschning C.J., Weiss S., et al. The mucosal adjuvant macrophage-activating lipopeptide-2 directly stimulates B lymphocytes via the TLR2 without the need of accessory cells. Journal of Immunology 2005, 174(10):6308-6313.
22. Liang Y., Hasturk H., Elliot J., Noronha A., Liu X., Wetzler L.M., et al. Toll-like receptor 2 induces mucosal homing receptor expression and IgA production by human B cells. Clinical Immunology 2011, 138(1):33-40.
23. Cashman S.B., Morgan J.G. Transcriptional analysis of Toll-like receptors expression in M cells. Molecular Immunology 2009, 47(2-3):365-372.
24. Chabot S.M., Chernin T.S., Shawi M., Wagner J., Farrant S., Burt D.S., et al. TLR2 activation by proteosomes promotes uptake of particulate vaccines at mucosal surfaces. Vaccine 2007, 25(29):5348-5358.